TCR-Engineered iNKT Cells Induce Robust Antitumor Response by Dual Targeting Cancer and Suppressive Myeloid Cells

Investigators showed that harnessing invariant natural killer T (iNKT) cells with a second T cell receptor (TCR) specific for a tumor-associated peptide generated bispecific effectors for CD1d- and major histocompatibility complex–restricted antigens in vitro.